Triggering TLR signaling in vaccination

Trends in Immunology

Volumn 27, Issue 1, 2006, Pages 49-55

  Van Duin, David ^a   Medzhitov, Ruslan ^a   Shaw, Albert C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BETA DEFENSIN 2; CANCER VACCINE; DNA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OUTER SURFACE PROTEIN A; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL MIGRATION; CLINICAL TRIAL; CROSS PRESENTATION; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; INFECTION CONTROL; INFLUENZA; LYME DISEASE; NONHUMAN; REVIEW; TUBERCULOSIS; UPREGULATION; VACCINATION;

ANIMALS; CELL MOVEMENT; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VACCINATION;

EID: 30544448127     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2005.11.005     Document Type: Review

References (80)

1. F.E. Andre Vaccinology: past achievements, present roadblocks and future promises Vaccine 21 2003 593 595
2. K. Takeda Toll-like receptors Annu. Rev. Immunol. 21 2003 335 376
3. A. Iwasaki, and R. Medzhitov Toll-like receptor control of the adaptive immune responses Nat. Immunol. 5 2004 987 995
4. B. Spellberg, and J.E.J. Edwards Type 1/Type 2 immunity in infectious diseases Clin. Infect. Dis. 32 2001 76 102
5. S.C. Eisenbarth Lipopolysaccharide-enhanced, Toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen J. Exp. Med. 196 2002 1645 1651
6. H.D. Brightbill Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors Science 285 1999 732 736
7. G. Trinchieri Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat. Rev. Immunol. 3 2003 133 146
8. D. Jankovic In the absence of IL-12, CD4+ T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10-/- setting Immunity 16 2002 429 439
9. X. Zhu Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity Eur. J. Immunol. 34 2004 3102 3114
10. Y. Osorio, and H. Ghiasi Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge J. Virol. 79 2005 3297 3308
11. T.K. Means The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells J. Immunol. 170 2003 5165 5175
12. G.J. Randolph Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances Springer Semin. Immunopathol. 26 2005 273 287
13. N. Okada Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction Gene Ther. 12 2005 129 139
14. S.K. Eo Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands Vaccine 19 2001 4685 4693
15. M. Cella Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells Nature 388 1997 782 787
16. C.J. Hertz Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2 J. Immunol. 166 2001 2444 2450
17. K. Hoebe Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways Nat. Immunol. 4 2003 1223 1229
18. L. Diehl CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy Nat. Med. 5 1999 774 779
19. N. Yamaguchi Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production J. Immunol. 172 2004 1347 1354
20. Z. Chen DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy Cell. Immunol. 214 2001 60 71
21. J. Borst CD27 and CD70 in T cell and B cell activation Curr. Opin. Immunol. 17 2005 275 281
22. M. Schroder, and A.G. Bowie TLR3 in antiviral immunity: key player or bystander? Trends Immunol. 26 2005 462 468
23. O. Schulz Toll-like receptor 3 promotes cross-priming to virus-infected cells Nature 433 2005 887 892
24. A. Heit CpG-DNA aided cross-priming by cross-presenting B cells J. Immunol. 172 2004 1501 1507
25. S.K. Datta A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells J. Immunol. 170 2003 4102 4110
26. D.M. Klinman Use of CpG oligodeoxynucleotides as immune adjuvants Immunol. Rev. 199 2004 201 216
27. B. Spies Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice J. Immunol. 171 2003 5908 5912
28. S. Babiuk TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine Immunology 113 2004 114 120
29. D. Tudor TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines Vaccine 23 2005 1258 1264
30. H. Wagner The immunobiology of the TLR9 subfamily Trends Immunol. 25 2004 381 386
31. E.A. Leadbetter Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors Nature 416 2002 603 607
32. M. Heikenwalder Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration Nat. Med. 10 2004 187 192
33. K.W. Schjetne Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target J. Immunol. 171 2003 32 36
34. D.C. Jackson A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses Proc. Natl. Acad. Sci. U. S. A. 101 2004 15440 15445
35. C. Pasare, and R. Medzhitov Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells Science 299 2003 1033 1036
36. Y. Yang Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance Nat. Immunol. 5 2004 508 515
37. P. Serra CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells Immunity 19 2003 877 889
38. G. Peng Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function Science 309 2005 1380 1384
39. C-L. Ku Inherited disorders of human Toll-like receptor signaling: immunological implications Immunol. Rev. 203 2005 10 20
40. A.C. Steere Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant N. Engl. J. Med. 339 1998 209 215
41. Y. Bulut Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling J. Immunol. 167 2001 987 994
42. L. Alexopoulou Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice Nat. Med. 8 2002 878 884
43. A. Yoder Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of Toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge Infect. Immun. 71 2003 3894 3900
44. N.W.J. Schroder Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses J. Immunol. 173 2004 2683 2691
45. M.R-E-I. Benhnia Signaling through CD14 attenuates the inflammatory response to Borrelia burgdorferi, the agent of Lyme disease J. Immunol. 174 2005 1539 1548
46. G.A. Colditz Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature JAMA 271 1994 698 702
47. S. Tsuji Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of Toll-like receptors Infect. Immun. 68 2000 6883 6890
48. T.K. Means Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis J. Immunol. 163 1999 3920 3927
49. C.M. Fremond Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88 J. Clin. Invest. 114 2004 1790 1799
50. E. Latz Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human Toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity J. Immunol. 172 2004 2431 2438
51. P. Massari Cutting edge: immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent J. Immunol. 168 2002 1533 1537
52. T. Al-Bader Activation of human dendritic cells is modulated by components of the outer membranes of Neisseria meningitidis Infect. Immun. 71 2003 5590 5597
53. A.A.C. Lemckert Challenges in the search for an HIV vaccine Eur. J. Epidemiol. 19 2004 513 516
54. M. Tritel Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses J. Immunol. 171 2003 2538 2547
55. C.C. Wilson Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1 J. Immunol. 171 2003 5611 5623
56. N.M. Flynn Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection J. Infect. Dis. 191 2005 654 665
57. H-M. Liu Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor Blood 92 1998 3730 3736
58. H.J. Cho Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism Nat. Biotechnol. 8 2000 509 514
59. J. Kochling Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides Clin. Cancer Res. 9 2003 3142 3149
60. K. Heckelsmiller Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy Eur. J. Immunol. 32 2002 3235 3245
61. D.E. Speiser Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909 J. Clin. Invest. 115 2005 739 746
62. M. Shackleton The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand Cancer Immun. 4 2004 9 20
63. J.R. Baldridge Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents Expert Opin. Biol. Ther. 4 2004 1129 1138
64. A. Biragyn Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens J. Immunol. 167 2001 6644 6653
65. T. Akazawa Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice Cancer Res. 64 2004 757 764
66. N. Habal CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer Ann. Surg. Oncol. 8 2001 389 401
67. J.B. Vermorken Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial Lancet 353 1999 345 350
68. E. Stockfleth The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview Br. J. Dermatol. 149 Suppl. 66 2003 53 56
69. F.G.E. Perabo, and S.C. Muller Current and new strategies in immunotherapy for superficial bladder cancer Urology 64 2004 409 421
70. P.A. Sieling Toll-like receptor 2 ligands as adjuvants for human Th1 responses J. Immunol. 170 2003 194 200
71. O. Takeuchi Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway J. Immunol. 164 2000 554 557
72. M. Schnare Toll-like receptors control activation of adaptive immune responses Nat. Immunol. 2 2001 947 950
73. A. Biragyn Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2 Science 298 2002 1025 1029
74. M. Przetak Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice Vaccine 21 2003 961 970
75. S.J. McSorley Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo J. Immunol. 169 2002 3914 3919
76. A.K. Zuber Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA Vaccine 22 2004 1791 1798
77. M. Otero Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model Vaccine 22 2004 1782 1790
78. U. Wille-Reece Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses J. Immunol. 174 2005 7676 7683
79. J.M. Lund Recognition of single-stranded RNA viruses by Toll-like receptor 7 Proc. Natl. Acad. Sci. U. S. A. 101 2004 5598 5603
80. K. Bieback Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling J. Virol. 76 2002 8729 8736